nach oben

American Journal of Clinical Dermatology

Erschienen in:

10.12.2020 | Review Article

Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review

verfasst von: Kevin Yang, Allen S. W. Oak, Boni E. Elewski

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Psoriasis is a common inflammatory skin disease with multiple comorbidities, including psoriatic arthritis and coronary artery disease, that can severely impact an individual’s quality of life and daily functioning. In recent years, enhanced understanding of the pathogenesis of psoriasis, especially the role of T helper 17 cells, has resulted in the development of new classes of biologic drugs targeting modulators along its disease pathway. Among these, inhibitors of interleukin-23 (e.g., ustekinumab, guselkumab, tildrakizumab, and risankizumab) have emerged as safe and effective options for the treatment of moderate-to-severe plaque psoriasis; ustekinumab and guselkumab have additionally been approved to treat psoriatic arthritis. Selective interleukin-23 inhibitors require less frequent dosing than interleukin-17 inhibitors and may possess a more favorable risk profile without an increased risk of candidiasis or inflammatory bowel disease. Overall, these highly effective medications are contributing to a rising standard for psoriasis outcomes through resolution of skin lesions and joint manifestations and improvement of patient quality of life.

Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–6. https://doi.org/10.1016/j.jaad.2013.11.013.CrossRefPubMed

Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States: a systematic review. JAMA Dermatol. 2015;151(6):651–8. https://doi.org/10.1001/jamadermatol.2014.3593.CrossRefPubMed

Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509. https://doi.org/10.1056/NEJMra0804595.CrossRefPubMed

Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475. https://doi.org/10.3390/ijms20061475.CrossRefPubMedCentral

Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073–113. https://doi.org/10.1016/j.jaad.2018.11.058.CrossRefPubMed

Mease PJ, Gladman DD, Papp KA, Khraishi MM, Thaçi D, Behrens F, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013;69(5):729–35. https://doi.org/10.1016/j.jaad.2013.07.023.CrossRefPubMed

Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957–70. https://doi.org/10.1056/NEJMra1505557.CrossRefPubMed

Bos JD, Hulsebosch HJ, Krieg SR, Bakker PM, Cormane RH. Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies. Arch Dermatol Res. 1983;275(3):181–9. https://doi.org/10.1007/bf00510050.CrossRefPubMed

Baker BS, Swain AF, Fry L, Valdimarsson H. Epidermal T lymphocytes and HLA-DR expression in psoriasis. Br J Dermatol. 1984;110(5):555–64. https://doi.org/10.1111/j.1365-2133.1984.tb04678.x.CrossRefPubMed

10.

Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Investig Dermatol. 1999;113(5):752–9. https://doi.org/10.1046/j.1523-1747.1999.00749.x.CrossRefPubMed

11.

Nestle FO, Turka LA, Nickoloff BJ. Characterization of dermal dendritic cells in psoriasis: autostimulation of T lymphocytes and induction of Th1 type cytokines. J Clin Investig. 1994;94(1):202–9. https://doi.org/10.1172/jci117308.CrossRefPubMed

12.

Detmar M, Orfanos CE. Tumor necrosis factor-alpha inhibits cell proliferation and induces class II antigens and cell adhesion molecules in cultured normal human keratinocytes in vitro. Arch Dermatol Res. 1990;282(4):238–45. https://doi.org/10.1007/bf00371643.CrossRefPubMed

13.

Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6(11):1123–32. https://doi.org/10.1038/ni1254.CrossRefPubMed

14.

Chiricozzi A, Suárez-Fariñas M, Fuentes-Duculan J, Cueto I, Li K, Tian S, et al. Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris. Br J Dermatol. 2016;174(1):136–45. https://doi.org/10.1111/bjd.14034.CrossRefPubMed

15.

Rizzo HL, Kagami S, Phillips KG, Kurtz SE, Jacques SL, Blauvelt A. IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. J Immunol. 2011;186(3):1495–502. https://doi.org/10.4049/jimmunol.1001001.CrossRefPubMed

16.

Nograles KE, Zaba LC, Guttman-Yassky E, Fuentes-Duculan J, Suárez-Fariñas M, Cardinale I, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol. 2008;159(5):1092–102. https://doi.org/10.1111/j.1365-2133.2008.08769.x.CrossRefPubMedPubMedCentral

17.

Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M, Nograles KE, Tian S, Cardinale I, et al. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Investig Dermatol. 2011;131(3):677–87. https://doi.org/10.1038/jid.2010.340.CrossRefPubMed

18.

Harper EG, Guo C, Rizzo H, Lillis JV, Kurtz SE, Skorcheva I, et al. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Investig Dermatol. 2009;129(9):2175–83. https://doi.org/10.1038/jid.2009.65.CrossRefPubMed

19.

Liu Y, Lagowski JP, Gao S, Raymond JH, White CR, Kulesz-Martin MF. Regulation of the psoriatic chemokine CCL20 by E3 ligases Trim32 and Piasy in keratinocytes. J Investig Dermatol. 2010;130(5):1384–90. https://doi.org/10.1038/jid.2009.416.CrossRefPubMed

20.

Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199(1):125–30. https://doi.org/10.1084/jem.20030451.CrossRefPubMedPubMedCentral

21.

Yawalkar N, Tscharner GG, Hunger RE, Hassan AS. Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis. J Dermatol Sci. 2009;54(2):99–105. https://doi.org/10.1016/j.jdermsci.2009.01.003.CrossRefPubMed

22.

Cheng JB, Sedgewick AJ, Finnegan AI, Harirchian P, Lee J, Kwon S, et al. Transcriptional programming of normal and inflamed human epidermis at single-cell resolution. Cell Rep. 2018;25(4):871–83. https://doi.org/10.1016/j.celrep.2018.09.006.CrossRefPubMedPubMedCentral

23.

Dolcino M, Ottria A, Barbieri A, Patuzzo G, Tinazzi E, Argentino G, et al. Gene expression profiling in peripheral blood cells and synovial membranes of patients with psoriatic arthritis. PLoS ONE. 2015;10(6):e0128262. https://doi.org/10.1371/journal.pone.0128262.CrossRefPubMedPubMedCentral

24.

Xu X, Davelaar N, Mus AM, Asmawidjaja PS, Hazes JMW, Baeten DLP, et al. IL-17A is produced by synovial fluid CD4+ but not CD8+ T cells after TCR activation and regulates different inflammatory mediators compared to TNF in a synovitis model of psoriatic arthritis. Arthritis Rheumatol. 2020;72(8):1303–13. https://doi.org/10.1002/art.41271.CrossRefPubMedPubMedCentral

25.

Chen L, Deshpande M, Grisotto M, Smaldini P, Garcia R, He Z, et al. Skin expression of IL-23 drives the development of psoriasis and psoriatic arthritis in mice. Sci Rep. 2020;10(1):8259. https://doi.org/10.1038/s41598-020-65269-6.CrossRefPubMedPubMedCentral

26.

Yang L, Fanok MH, Mediero-Munoz A, Fogli LK, Corciulo C, Abdollahi S, et al. Augmented Th17 differentiation leads to cutaneous and synovio-entheseal inflammation in a novel model of psoriatic arthritis. Arthritis Rheumatol. 2018;70(6):855–67. https://doi.org/10.1002/art.40447.CrossRefPubMedPubMedCentral

27.

Kim KW, Kim HR, Park JY, Park JS, Oh HJ, Woo YJ, et al. Interleukin-22 promotes osteoclastogenesis in rheumatoid arthritis through induction of RANKL in human synovial fibroblasts. Arthritis Rheum. 2012;64(4):1015–23. https://doi.org/10.1002/art.33446.CrossRefPubMed

28.

El-Zayadi AA, Jones EA, Churchman SM, Baboolal TG, Cuthbert RJ, El-Jawhari JJ, et al. Interleukin-22 drives the proliferation, migration and osteogenic differentiation of mesenchymal stem cells: a novel cytokine that could contribute to new bone formation in spondyloarthropathies. Rheumatology (Oxford). 2017;56(3):488–93. https://doi.org/10.1093/rheumatology/kew384.CrossRef

29.

Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356(6):580–92. https://doi.org/10.1056/NEJMoa062382.CrossRefPubMed

30.

Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665–74. https://doi.org/10.1016/s0140-6736(08)60725-4.CrossRefPubMed

31.

Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675–84. https://doi.org/10.1016/s0140-6736(08)60726-6.CrossRefPubMed

32.

Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362(2):118–28. https://doi.org/10.1056/NEJMoa0810652.CrossRefPubMed

33.

Langley RG, Lebwohl M, Krueger GG, Szapary PO, Wasfi Y, Chan D, et al. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. Br J Dermatol. 2015;172(5):1371–83. https://doi.org/10.1111/bjd.13469.CrossRefPubMed

34.

Kimball AB, Papp KA, Wasfi Y, Chan D, Bissonnette R, Sofen H, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. 2013;27(12):1535–45. https://doi.org/10.1111/jdv.12046.CrossRefPubMed

35.

Tsai TF, Ho JC, Song M, Szapary P, Guzzo C, Shen YK, et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci. 2011;63(3):154–63. https://doi.org/10.1016/j.jdermsci.2011.05.005.CrossRefPubMed

36.

Igarashi A, Kato T, Kato M, Song M, Nakagawa H. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol. 2012;39(3):242–52. https://doi.org/10.1111/j.1346-8138.2011.01347.x.CrossRefPubMed

37.

Zhu X, Zheng M, Song M, Shen YK, Chan D, Szapary PO, et al. Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS). J Drugs Dermatol. 2013;12(2):166–74.PubMed

38.

Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013;168(4):844–54. https://doi.org/10.1111/bjd.12214.CrossRefPubMed

39.

Sofen H, Smith S, Matheson RT, Leonardi CL, Calderon C, Brodmerkel C, et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol. 2014;133(4):1032–40. https://doi.org/10.1016/j.jaci.2014.01.025.CrossRefPubMed

40.

Gordon KB, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S, et al. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med. 2015;373(2):136–44. https://doi.org/10.1056/NEJMoa1501646.CrossRefPubMed

41.

Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–17. https://doi.org/10.1016/j.jaad.2016.11.041.CrossRefPubMed

42.

Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–31. https://doi.org/10.1016/j.jaad.2016.11.042.CrossRefPubMed

43.

Griffiths CEM, Papp KA, Song M, Miller M, You Y, Shen YK, et al. Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1. J Dermatol Treat. 2020. https://doi.org/10.1080/09546634.2020.1782817.CrossRef

44.

Reich K, Armstrong AW, Foley P, Song M, Miller M, Shen YK, et al. Maintenance of response through up to 4 years of continuous guselkumab treatment of psoriasis in the VOYAGE 2 phase 3 study. Am J Clin Dermatol. 2020;1(6):881–90. https://doi.org/10.1007/s40257-020-00555-7.CrossRef

45.

Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831–9. https://doi.org/10.1016/s0140-6736(19)31773-8.CrossRefPubMed

46.

Ohtsuki M, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study. J Dermatol. 2018;45(9):1053–62. https://doi.org/10.1111/1346-8138.14504.CrossRefPubMedPubMedCentral

47.

Langley RG, Tsai TF, Flavin S, Song M, Randazzo B, Wasfi Y, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018;178(1):114–23. https://doi.org/10.1111/bjd.15750.CrossRefPubMed

48.

Ferris LK, Ott E, Jiang J, Hong HC, Li S, Han C, et al. Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study. J Dermatol Treat. 2020;31(2):152–9. https://doi.org/10.1080/09546634.2019.1587145.CrossRef

49.

Papp K, Thaçi D, Reich K, Riedl E, Langley RG, Krueger JG, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015;173(4):930–9. https://doi.org/10.1111/bjd.13932.CrossRefPubMed

50.

Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Thaçi D, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276–88. https://doi.org/10.1016/s0140-6736(17)31279-5.CrossRefPubMed

51.

Reich K, Warren RB, Iversen L, Puig L, Pau-Charles I, Igarashi A, et al. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. Br J Dermatol. 2020;182(3):605–17. https://doi.org/10.1111/bjd.18232.CrossRefPubMed

52.

Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Krueger JG, Lacour JP, et al. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med. 2017;376(16):1551–60. https://doi.org/10.1056/NEJMoa1607017.CrossRefPubMed

53.

Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–61. https://doi.org/10.1016/s0140-6736(18)31713-6.CrossRefPubMed

54.

Reich K, Gooderham M, Thaçi D, Crowley JJ, Ryan C, Krueger JG, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019;394(10198):576–86. https://doi.org/10.1016/s0140-6736(19)30952-3.CrossRefPubMed

55.

Warren RB, Blauvelt A, Poulin Y, Beeck S, Kelly M, Wu T, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase 3, randomised, open-label, efficacy assessor-blinded clinical trial. Br J Dermatol. 2020. https://doi.org/10.1111/bjd.19341.CrossRefPubMedPubMedCentral

56.

Ohtsuki M, Fujita H, Watanabe M, Suzaki K, Flack M, Huang X, et al. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: results from the SustaIMM phase 2/3 trial. J Dermatol. 2019;46(8):686–94. https://doi.org/10.1111/1346-8138.14941.CrossRefPubMedPubMedCentral

57.

Blauvelt A, Leonardi CL, Gooderham M, Papp KA, Philipp S, Wu JJ, et al. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(6):1–11. https://doi.org/10.1001/jamadermatol.2020.0723.CrossRefPubMedCentral

58.

Reich K, Rich P, Maari C, Bissonnette R, Leonardi C, Menter A, et al. Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study. Br J Dermatol. 2019;181(1):88–95. https://doi.org/10.1111/bjd.17628.CrossRefPubMed

59.

Lilly's mirikizumab superior to Cosentyx^® (secukinumab) in a phase 3 study for patients with moderate to severe plaque psoriasis. https://investor.lilly.com/node/43481/pdf. Accessed 2 Aug 2020.

60.

Ma C, Panaccione R, Khanna R, Feagan BG, Jairath V. IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn’s disease? Best Pract Res Clin Gastroenterol. 2019;38–39:101604. https://doi.org/10.1016/j.bpg.2019.02.006.CrossRefPubMed

61.

Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373(9664):633–40. https://doi.org/10.1016/s0140-6736(09)60140-9.CrossRefPubMed

62.

McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382(9894):780–9. https://doi.org/10.1016/s0140-6736(13)60594-2.CrossRefPubMed

63.

Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73(6):990–9. https://doi.org/10.1136/annrheumdis-2013-204655.CrossRefPubMedPubMedCentral

64.

Araujo EG, Englbrecht M, Hoepken S, Finzel S, Kampylafka E, Kleyer A, et al. Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study. Semin Arthritis Rheum. 2019;48(4):632–7. https://doi.org/10.1016/j.semarthrit.2018.05.011.CrossRefPubMed

65.

Deodhar A, Gensler LS, Sieper J, Clark M, Calderon C, Wang Y, et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol. 2019;71(2):258–70. https://doi.org/10.1002/art.40728.CrossRefPubMed

66.

Janssen. Tremfya^® (guselkumab) approved by U.S. Food and Drug Administration as the first selective interleukin (IL)-23 inhibitor for active psoriatic arthritis. https://www.janssen.com/us/sites/www_janssen_com_usa/files/tremfya_psa_fda_approval_press_release_071420_final.pdf. Accessed 31 July 2020.

67.

Deodhar A, Gottlieb AB, Boehncke WH, Dong B, Wang Y, Zhuang Y, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2018;391(10136):2213–24. https://doi.org/10.1016/s0140-6736(18)30952-8.CrossRefPubMed

68.

Deodhar A, Helliwell PS, Boehncke WH, Kollmeier AP, Hsia EC, Subramanian RA, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1115–25. https://doi.org/10.1016/s0140-6736(20)30265-8.CrossRefPubMed

69.

Mease PJ, Rahman P, Gottlieb AB, Kollmeier AP, Hsia EC, Xu XL, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126–36. https://doi.org/10.1016/s0140-6736(20)30263-4.CrossRefPubMed

70.

Mease PJ, Gladman DD, Deodhar A, McGonagle DG, Nash P, Boehncke WH, et al. Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study. RMD Open. 2020. https://doi.org/10.1136/rmdopen-2020-001217.CrossRefPubMedPubMedCentral

71.

Langley RG, Thaçi D, Reich K, Papp K, Mehta A, Li Q, et al. FRI0445 tildrakizumab treatment improved measures of psoriatic arthritis in adults with chronic plaque psoriasis. Ann Rheum Dis. 2016;75(Suppl. 2):596. https://doi.org/10.1136/annrheumdis-2016-eular.3342.CrossRef

72.

Ismail FF, May J, Moi J, Sinclair R. Clinical improvement in psoriatic nail disease and psoriatic arthritis with tildrakizumab treatment. Dermatol Ther. 2020;33(2):e13216. https://doi.org/10.1111/dth.13216.CrossRefPubMed

73.

Mease PJ, Chohan S, Fructuoso FJG, Chou RC, Nograles KE, Mendelsohn AM, et al. LB0002 Randomised, double-blind, placebo-controlled, multiple-dose, phase 2B study to demonstrate the safety and efficacy of tildrakizumab, a high-affinity anti-interleukin-23p19 monoclonal antibody, in patients with active psoriatic arthritis. Ann Rheum Dis. 2019;78(Suppl. 2):78. https://doi.org/10.1136/annrheumdis-2019-eular.8669.CrossRef

74.

Mease PJ, Kellner H, Morita A, Kivitz AJ, Papp KA, Aslanyan S, et al. OP0307 Efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial. Ann Rheum Dis. 2018;77(Suppl. 2):200. https://doi.org/10.1136/annrheumdis-2018-eular.2140.CrossRef

75.

Baeten D, Østergaard M, Wei JC-C, Sieper J, Järvinen P, Tam L-S, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis. 2018;77(9):1295. https://doi.org/10.1136/annrheumdis-2018-213328.

76.

Sawyer LM, Malottki K, Sabry-Grant C, Yasmeen N, Wright E, Sohrt A, et al. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. PLoS ONE. 2019;14(8):e0220868. https://doi.org/10.1371/journal.pone.0220868.CrossRefPubMedPubMedCentral

77.

Du Jardin KG, Hurtado Lopez P, Lange M, McCool R, Maeso Naval S, Quickert S. A systematic literature review and Bucher indirect comparison: tildrakizumab versus guselkumab. J Health Econ Outcomes Res. 2020;7(2):123–9. https://doi.org/10.36469/jheor.2020.13671.CrossRefPubMedPubMedCentral

78.

Zhou L, Wang Y, Wan Q, Perron D, Zhu R, Wang L, et al. 394 IL-23 antibodies in psoriasis: a non-clinical perspective. J Investig Dermatol. 2019;139(9 Suppl.):S282. https://doi.org/10.1016/j.jid.2019.07.396.CrossRef

79.

Kamaria M, Liao W, Koo JY. How long does the benefit of biologics last? An update on time to relapse and potential for rebound of biologic agents for psoriasis. Psoriasis Forum. 2010;16(2):36–42.CrossRef

80.

Warren RB, Carrascosa JM, Fumero E, Schoenenberger A, Lebwohl MG, Szepietowski JC, et al. Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post-hoc analysis through 64 weeks from reSURFACE 1 trial. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16964.CrossRefPubMedPubMedCentral

81.

Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Care Res. 2019;71(1):2–29. https://doi.org/10.1002/acr.23789.CrossRef

82.

Piskin G, Sylva-Steenland RM, Bos JD, Teunissen MB. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol. 2006;176(3):1908–15. https://doi.org/10.4049/jimmunol.176.3.1908.CrossRefPubMed

83.

Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018;201(6):1605–13. https://doi.org/10.4049/jimmunol.1800013.CrossRefPubMedPubMedCentral

84.

Guo W, Luo C, Wang C, Zhu Y, Wang X, Gao X, et al. Protection against Th17 cells differentiation by an interleukin-23 receptor cytokine-binding homology region. PLoS ONE. 2012;7(9):e45625. https://doi.org/10.1371/journal.pone.0045625.CrossRefPubMedPubMedCentral

85.

Abdo AIK, Tye GJ. Interleukin 23 and autoimmune diseases: current and possible future therapies. Inflamm Res. 2020;69(5):463–80. https://doi.org/10.1007/s00011-020-01339-9.CrossRefPubMed

86.

Girolomoni G, Strohal R, Puig L, Bachelez H, Barker J, Boehncke WH, et al. The role of IL-23 and the IL-23/T(H) 17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(10):1616–26. https://doi.org/10.1111/jdv.14433.CrossRefPubMedPubMedCentral

87.

Kimball AB, Gordon KB, Fakharzadeh S, Yeilding N, Szapary PO, Schenkel B, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol. 2012;166(4):861–72. https://doi.org/10.1111/j.1365-2133.2012.10901.x.CrossRefPubMed

88.

Maliyar K, O’Toole A, Gooderham MJ. Long-term single center experience in treating plaque psoriasis with guselkumab. J Cutan Med Surg. 2020. https://doi.org/10.1177/1203475420932514.CrossRefPubMed

89.

Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol. 2020;182(6):1348–58. https://doi.org/10.1111/bjd.18851.CrossRefPubMedPubMedCentral

90.

Levin AA, Gottlieb AB. Specific targeting of interleukin-23p19 as effective treatment for psoriasis. J Am Acad Dermatol. 2014;70(3):555–61. https://doi.org/10.1016/j.jaad.2013.10.043.CrossRefPubMed

91.

Gately MK, Renzetti LM, Magram J, Stern AS, Adorini L, Gubler U, et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol. 1998;16:495–521. https://doi.org/10.1146/annurev.immunol.16.1.495.CrossRefPubMed

92.

Crowley JJ, Warren RB, Cather JC. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2019;33(9):1676–84. https://doi.org/10.1111/jdv.15653.CrossRefPubMedPubMedCentral

93.

Zhu Y, Hu C, Lu M, Liao S, Marini JC, Yohrling J, et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2009;49(2):162–75. https://doi.org/10.1177/0091270008329556.CrossRefPubMed

94.

Zhu Y, Xu Y, Zhuang Y, Piantone A, Shu C, Chen D, et al. Evaluating potential disease-mediated protein-drug interactions in patients with moderate-to-severe plaque psoriasis receiving subcutaneous guselkumab. Clin Transl Sci. 2020. https://doi.org/10.1111/cts.12807.CrossRefPubMedPubMedCentral

95.

Khalilieh S, Hussain A, Montgomery D, Levine V, Shaw PM, Bodrug I, et al. Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis. Br J Clin Pharmacol. 2018;84(10):2292–302. https://doi.org/10.1111/bcp.13670.CrossRefPubMedPubMedCentral

96.

Khatri A, Cheng L, Camez A, Ignatenko S, Pang Y, Othman AA. Lack of effect of 12-week treatment with risankizumab on the pharmacokinetics of cytochrome P450 probe substrates in patients with moderate to severe chronic plaque psoriasis. Clin Pharmacokinet. 2019;58(6):805–14. https://doi.org/10.1007/s40262-018-0730-x.CrossRefPubMed

97.

Evangelatos G, Koulouri V, Iliopoulos A, Fragoulis GE. Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors. Ther Adv Musculoskelet Dis. 2020. https://doi.org/10.1177/1759720x20930116.CrossRefPubMedPubMedCentral

98.

Fowler E, Ghamrawi RI, Ghiam N, Liao W, Wu JJ. Risk of tuberculosis reactivation during interleukin-17 inhibitor therapy for psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2020;34(7):1449–56. https://doi.org/10.1111/jdv.16254.CrossRefPubMed

99.

Khader SA, Cooper AM. IL-23 and IL-17 in tuberculosis. Cytokine. 2008;41(2):79–83. https://doi.org/10.1016/j.cyto.2007.11.022.CrossRefPubMedPubMedCentral

100.

Tsai TF, Ho V, Song M, Szapary P, Kato T, Wasfi Y, et al. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br J Dermatol. 2012;167(5):1145–52. https://doi.org/10.1111/j.1365-2133.2012.11142.x.CrossRefPubMed

101.

Puig L, Tsai TF, Bhutani T, Uy J, Ramachandran P, Song M, et al. Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials. J Eur Acad Dermatol Venereol. 2020;34(8):1744–9. https://doi.org/10.1111/jdv.16460.CrossRefPubMed

102.

Ryan C, Leonardi CL, Krueger JG, Kimball AB, Strober BE, Gordon KB, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011;306(8):864–71. https://doi.org/10.1001/jama.2011.1211.CrossRefPubMed

103.

Reich K, Langley RG, Lebwohl M, Szapary P, Guzzo C, Yeilding N, et al. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol. 2011;164(4):862–72. https://doi.org/10.1111/j.1365-2133.2011.10257.x.CrossRefPubMed

104.

Tzellos T, Kyrgidis A, Zouboulis CC. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol. 2013;27(5):622–7. https://doi.org/10.1111/j.1468-3083.2012.04500.x.CrossRefPubMed

105.

Gordon KB, Langley RG, Gottlieb AB, Papp KA, Krueger GG, Strober BE, et al. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol. 2012;132(2):304–14. https://doi.org/10.1038/jid.2011.304.CrossRefPubMed

106.

Dommasch ED, Troxel AB, Gelfand JM. Major cardiovascular events associated with anti-IL 12/23 agents: a tale of two meta-analyses. J Am Acad Dermatol. 2013;68(5):863–5. https://doi.org/10.1016/j.jaad.2013.01.011.CrossRefPubMed

107.

Poizeau F, Nowak E, Kerbrat S, Le Nautout B, Droitcourt C, Drici MD, et al. Association between early severe cardiovascular events and the initiation of treatment with the anti-interleukin 12/23p40 antibody ustekinumab. JAMA Dermatol. 2020. https://doi.org/10.1001/jamadermatol.2020.2977.CrossRefPubMed

108.

Lebwohl M, Rivera-Oyola R, Murrell DF. Should biologics for psoriasis be interrupted in the era of COVID-19? J Am Acad Dermatol. 2020;82(5):1217–8. https://doi.org/10.1016/j.jaad.2020.03.031.CrossRefPubMedPubMedCentral

109.

Price KN, Frew JW, Hsiao JL, Shi VY. COVID-19 and immunomodulator/immunosuppressant use in dermatology. J Am Acad Dermatol. 2020;82(5):e173–5. https://doi.org/10.1016/j.jaad.2020.03.046.CrossRefPubMedPubMedCentral

110.

Fieldhouse KA, Ukaibe S, Crowley EL, Khanna R, O’Toole A, Gooderham MJ. Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors. Drugs Context. 2020. https://doi.org/10.7573/dic.2020-2-1.CrossRefPubMedPubMedCentral

111.

Macaluso FS, Orlando A, Cottone M. Anti-interleukin-12 and anti-interleukin-23 agents in Crohn’s disease. Expert Opin Biol Ther. 2019;19(2):89–98. https://doi.org/10.1080/14712598.2019.1561850.CrossRefPubMed

112.

Conti HR, Gaffen SL. IL-17-mediated immunity to the opportunistic fungal pathogen Candida albicans. J Immunol. 2015;195(3):780–8. https://doi.org/10.4049/jimmunol.1500909.CrossRefPubMedPubMedCentral

113.

Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–72. https://doi.org/10.1016/j.jaad.2018.11.057.CrossRefPubMed

114.

Siegel SAR, Winthrop KL, Ehst BD, Ortega LA. Ustekinumab use in patients with severe psoriasis co-infected with hepatitis B and/or C. Br J Dermatol. 2019;180(5):1232–3. https://doi.org/10.1111/bjd.17444.CrossRefPubMed

115.

Solay AH, Acar A, Eser F, Kuşcu F, Tütüncü EE, Kul G, et al. Reactivation rates in patients using biological agents, with resolved HBV infection or isolated anti-HBc IgG positivity. Turk J Gastroenterol. 2018;29(5):561–5. https://doi.org/10.5152/tjg.2018.18032.CrossRefPubMedPubMedCentral

116.

Ting SW, Chen YC, Huang YH. Risk of hepatitis B reactivation in patients with psoriasis on ustekinumab. Clin Drug Investig. 2018;38(9):873–80. https://doi.org/10.1007/s40261-018-0671-z.CrossRefPubMed

117.

Bartos G, Cline A, Beroukhim K, Burrall BA, Feldman SR. Current biological therapies for use in HIV-positive patients with psoriasis: case report of gesulkumab used and review. Dermatol Online J. 2018;24(11):13030/qt3db748cg.

118.

Montes-Torres A, Aparicio G, Rivera R, Vilarrasa E, Marcellán M, Notario J, et al. Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study. J Dermatol Treat. 2019;30(5):461–5. https://doi.org/10.1080/09546634.2018.1535690.CrossRef

119.

Stelara^® (ustekinumab) [package insert]. Horsham (PA): Janssen; 2016.

120.

Tremfya^® (guselkumab) [package insert]. Horsham (PA): Janssen; 2017.

121.

Ilumya^® (tildrakizumab-asmn) [package insert]. Whitehouse Station (NJ): Merck; 2018.

122.

Skyrizi^® (risankizumab-rzaa) [package insert]. North Chicago (IL): AbbVie; 2019.

123.

Tyring SK, Spelman L, Igarashi A, Ohtsuki M, Ciichanowitz N, La Rosa C, et al. Efficacy and safety of long-term tildrakizumab for plaque psoriasis: 3-year results from reSURFACE 1. J Am Acad Dermatol. 2019;81(4 Suppl. 1):AB431. https://doi.org/10.1016/j.jaad.2019.10.026.

124.

Gooderham M, Papp KA, Blauvelt A, Thaçi D, Ciichanowitz N, Li Q, et al. Efficacy and safety of long-term tildrakizumab for plaque psoriasis: 3-year results from reSURFACE 2. J Am Acad Dermatol. 2019;81(4):AB431. https://doi.org/10.1016/j.jaad.2019.10.027.CrossRef

Titel: Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review
verfasst von: Kevin Yang
Allen S. W. Oak
Boni E. Elewski
Publikationsdatum: 10.12.2020
Verlag: Springer International Publishing
Erschienen in: American Journal of Clinical Dermatology / Ausgabe 2/2021
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI: https://doi.org/10.1007/s40257-020-00578-0

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Bildnachweise

Die Leitlinien für Ärztinnen und Ärzte, Nahaufnahme Rosazea auf der Wange/© Alessandro Grandini / stock.adobe.com (Symbolbild mit Fotomodell), Eine Tätowierung wird mit roter Farbe ausgefüllt/© nagaets / stock.adobe.com (Symbolbild mit Fotomodell), Operation/© Peakstock / Stock.adobe.com (Symbolbild mit Fotomodellen), Rechte Aa. carotis interna mit Wandverdickung bei Riesenzellarteriitis/© Kisyova H et al. | all rights reserved Springer Medizin Verlag GmbH

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

Reply to: Cohen and Ross: “Laser-Induced Chrysiasis: A Unique Adverse Event Associated with Q-Switched Lasers”

Oral Antibiotics for Acne

Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?

Pediatric Mastocytosis: Recognition and Management

Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum

Use of Complementary and Alternative Medicines by Patients with Psoriasis: Results from a Study with 2562 Patients